Meeting
2024 ASCO Annual Meeting
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.
Authors
Lijuan Chen
Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Lijuan Chen , Linyu Yang , Jie Wang , Rui Liang , He Li , Mengke Liu , Yi Wen , Lin Liu , Xiaoqiong Tang , Jieping Li , Xun Lai , Huijing Wu , Yajun Li , Shihua Huang , Lihua Yang , Ke Tan , Li Wang , Ting Niu , Weili Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05563844
Citation
J Clin Oncol 42, 2024 (suppl 17; abstr LBA7074)
DOI
10.1200/JCO.2024.42.17_suppl.LBA7074
Abstract #
LBA7074
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
First Author: Aki Morikawa
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2023 ASCO Annual Meeting
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
First Author: David Lavie